This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
CureVac 대차대조표 건전성
재무 건전성 기준 점검 6/6
CureVac 의 총 주주 지분은 €871.2M 이고 총 부채는 €0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 €1.1B 및 €267.4M 입니다. CureVac 의 EBIT는 €182.1M 이며 이자보상배율은 -27.7 입니다. €416.1M 의 현금 및 단기 투자금을 보유하고 있습니다.
핵심 정보
0%
부채/자본 비율
€0
부채
| 이자보상배율 | -27.7x |
| 현금 | €416.09m |
| 자본 | €871.23m |
| 총부채 | €267.39m |
| 총자산 | €1.14b |
최근 재무 건전성 업데이트
분석 기사 • Jul 05
We're Hopeful That CureVac (NASDAQ:CVAC) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...분석 기사 • Mar 20
We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...분석 기사 • May 29
Will CureVac (NASDAQ:CVAC) Spend Its Cash Wisely?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Recent updates
분석 기사 • Jun 15
There's No Escaping CureVac N.V.'s (NASDAQ:CVAC) Muted Revenues Despite A 50% Share Price Rise
Despite an already strong run, CureVac N.V. ( NASDAQ:CVAC ) shares have been powering on, with a gain of 50% in the...분석 기사 • May 27
The Strong Earnings Posted By CureVac (NASDAQ:CVAC) Are A Good Indication Of The Strength Of The Business
CureVac N.V. ( NASDAQ:CVAC ) recently posted some strong earnings, and the market responded positively. We did some...
새로운 내러티브 • May 06
GSK Milestones And Tech Focus Will Shape Oncology Amid Risks
Strategic focus on innovation and R&D in oncology and infectious diseases positions CureVac for potential high-growth opportunities and revenue enhancement.분석 기사 • May 01
CureVac N.V. (NASDAQ:CVAC) Shares Fly 31% But Investors Aren't Buying For Growth
Those holding CureVac N.V. ( NASDAQ:CVAC ) shares would be relieved that the share price has rebounded 31% in the last...Seeking Alpha • Mar 28
CureVac: Patent Win Notable, But Won't Answer More Fundamental Questions
Summary CureVac N.V.'s restructuring deal with GSK and workforce reduction suggest financial struggles, with net losses reported from 2020-2023; however, the GSK deal secures funding until 2028. CVAC stock received a boost yesterday after winning a key patent dispute against BioNTech, potentially leading to significant damages if infringement is confirmed in 2025. Despite the legal win, CureVac's pipeline remains weak, with only one wholly-owned asset in clinical development, raising concerns about its long-term viability. Upgrading CureVac stock from "Sell" to "Hold" due to the potential financial windfall from the patent dispute, though fundamental issues remain unresolved. Read the full article on Seeking AlphaSeeking Alpha • Jan 08
CureVac: Latest GBM Data Bodes Well For Next Program Check Point
Summary CureVac N.V.'s CVGBM vaccine showed positive safety and immunogenicity data in Part A of its phase 1 study for resected glioblastoma, with no dose-limiting toxicities. Key catalysts include Part B CVGBM resectable GBM data release in 2nd half of 2025 and possible phase 2 study initiation in 2nd half of 2026. The company is also developing a vaccine for squamous NSCLC, with an IND filing expected in the 1st half of 2025 and phase 1 study initiation in the 2nd half of 2025. Financially strong, with $208.8M in cash plus additional funds of $412.53M from GlaxoSmithKline agreement being redone; the Company believes that it has enough cash on hand to fund operations into 2028. Read the full article on Seeking Alpha분석 기사 • Jan 04
Subdued Growth No Barrier To CureVac N.V. (NASDAQ:CVAC) With Shares Advancing 25%
CureVac N.V. ( NASDAQ:CVAC ) shares have had a really impressive month, gaining 25% after a shaky period beforehand...Seeking Alpha • Oct 08
CureVac: Back To Square One
Summary Today, we're circling back to a development company called CureVac N.V. The company recently agreed to a deal with GSK plc, that involved a huge upfront payment, as well as potential milestone payouts and royalties. That left CureVac with a huge amount of cash on its balance sheet but pushed its pipeline back to very early-stage development. Read the full article on Seeking Alpha분석 기사 • Sep 16
CureVac N.V.'s (NASDAQ:CVAC) Share Price Could Signal Some Risk
It's not a stretch to say that CureVac N.V.'s ( NASDAQ:CVAC ) price-to-sales (or "P/S") ratio of 10.6x right now seems...분석 기사 • Aug 03
CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 93% Above Its Share Price
Key Insights The projected fair value for CureVac is US$6.64 based on 2 Stage Free Cash Flow to Equity Current share...분석 기사 • Jul 05
We're Hopeful That CureVac (NASDAQ:CVAC) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Seeking Alpha • Jul 04
CureVac: GSK's Deal For Infectious Disease Assets Is A Long-Shot For Both Pharmas
Summary CureVac's share price has plummeted over 90% in the past five years due to vaccine efficacy issues and legal disputes. The mRNA specialist was unable to develop a successful COVID vaccine, unlike rivals Moderna and BioNTech. GSK's $400m purchase of CureVac's infectious disease vaccine candidates, announced yesterday, provides a financial lifeline with milestones, and royalties pledged >$1bn. Despite the deal, CureVac still faces challenges in catching up to competitors like Moderna and BioNTech, making a "sell" recommendation appropriate at this time, in my view. Read the full article on Seeking Alpha분석 기사 • Jun 01
Optimistic Investors Push CureVac N.V. (NASDAQ:CVAC) Shares Up 47% But Growth Is Lacking
CureVac N.V. ( NASDAQ:CVAC ) shareholders would be excited to see that the share price has had a great month, posting a...분석 기사 • Mar 20
We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Seeking Alpha • Mar 08
CureVac: No Momentum In Sight
Summary CureVac faces challenges as a German court invalidates one of their key mRNA technology patents, raising concerns about their ability to compete in the mRNA space. The invalidated patent relates to an invention that many argue was not a genuine "invention" as the concepts and technologies were already well-known in the scientific community. CureVac's future prospects rely heavily on their partnerships, such as their joint effort with GSK for influenza and COVID vaccines, and their RNA Printer technology for point-of-care production of RNA therapeutics. Read the full article on Seeking Alpha분석 기사 • Aug 26
What Does The Future Hold For CureVac N.V. (NASDAQ:CVAC)? These Analysts Have Been Cutting Their Estimates
One thing we could say about the analysts on CureVac N.V. ( NASDAQ:CVAC ) - they aren't optimistic, having just made a...분석 기사 • Jun 14
CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 89% Above Its Share Price
Key Insights The projected fair value for CureVac is US$19.46 based on 2 Stage Free Cash Flow to Equity CureVac is...분석 기사 • May 01
Some Analysts Just Cut Their CureVac N.V. (NASDAQ:CVAC) Estimates
The latest analyst coverage could presage a bad day for CureVac N.V. ( NASDAQ:CVAC ), with the analysts making...분석 기사 • Apr 29
Analysts Have Lowered Expectations For CureVac N.V. (NASDAQ:CVAC) After Its Latest Results
The analysts might have been a bit too bullish on CureVac N.V. ( NASDAQ:CVAC ), given that the company fell short of...분석 기사 • Jan 08
An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 46% Undervalued
Key Insights CureVac's estimated fair value is €15.4 based on 2 Stage Free Cash Flow to Equity Current share price of...Seeking Alpha • Aug 18
CureVac BV reports Q2 results
CureVac BV press release (NASDAQ:CVAC): Q2 Pre-tax loss of €57.6M Revenue of €20.1M (-10.3% Y/Y). Cash position of €573.6 million as of June 30, 2022; decreasing headwind of wind-down costs for first-generation COVID-19 vaccine program Shares +1.37% PM.Seeking Alpha • Jul 05
CureVac claims patent rights for Pfizer/BioNTech COVID-19 vaccine
German biotech CureVac N.V. (NASDAQ:CVAC) announced on Tuesday that the company filed a lawsuit in Germany over the infringement of certain intellectual property rights related to the COVID-19 vaccine developed by its local rival BioNTech (BNTX) and U.S. pharma giant Pfizer (PFE). The case was filed in the German Regional Court in Düsseldorf against BioNTech (BNTX) and two of its subsidiaries, CureVac (CVAC) said, noting it would fair compensation for the alleged violations. While CureVac (CVAC) has added ~1%, both BioNTech (BNTX) and Pfizer (PFE) have lost ~1% in the pre-market so far. However, the company said that it would not seek an injunction or resort to a legal action that could disrupt the production and sales of the blockbuster vaccine. The IP rights titled EP 1 857 122 B1, DE 20 2015 009 961 U1 relate to the development of mRNA, the compound behind the Pfizer (PFE)/ BioNTech (BNTX) COVID-19 vaccine.분석 기사 • May 29
Will CureVac (NASDAQ:CVAC) Spend Its Cash Wisely?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...분석 기사 • May 02
Analysts Are Betting On CureVac N.V. (NASDAQ:CVAC) With A Big Upgrade This Week
Celebrations may be in order for CureVac N.V. ( NASDAQ:CVAC ) shareholders, with the analysts delivering a significant...분석 기사 • Oct 28
A Look At The Intrinsic Value Of CureVac N.V. (NASDAQ:CVAC)
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of CureVac N.V...Seeking Alpha • Sep 01
CureVac: Wait For Concrete News Before Investing
In the same way as Moderna and BioNTech, CureVac makes use of mRNA to develop COVID vaccines. However, in contrast to these two illustrious peers which are at commercialization stage, CureVac's first generation vaccine candidate has exhibited a much lower efficiency against infection. Following the August 31 update on CVnCoV, the biotech still makes for an investment case as it is developing a second generation vaccine and is also diversified on cancer cures. The cash position is also good. However, in view of past deceptions around efficacy, it is better to wait for concrete news before purchasing the stock.분석 기사 • Jun 13
An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 31% Undervalued
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of CureVac N.V...재무 상태 분석
단기부채: CVAC 의 단기 자산 ( €873.1M )이 단기 부채( €236.2M ).
장기 부채: CVAC의 단기 자산(€873.1M)이 장기 부채(€31.2M)를 초과합니다.
부채/자본 비율 추이 및 분석
부채 수준: CVAC 부채가 없습니다.
부채 감소: CVAC는 5년 전에 부채가 없었습니다.
부채 범위: CVAC 은 부채가 없으므로 영업현금흐름으로 충당할 필요가 없습니다.
이자 보장: CVAC 에는 부채가 없으므로 이자 지불에 대한 보장은 문제가 되지 않습니다.
대차대조표
건전한 기업 찾아보기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2025/12/17 22:26 |
| 종가 | 2025/12/17 00:00 |
| 수익 | 2025/09/30 |
| 연간 수익 | 2024/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
CureVac N.V.는 4명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Rajan Sharma | Goldman Sachs |
| Eun Kyung Yang | Jefferies LLC |
| Roger Song | Jefferies LLC |